ArticleFrontiers in immunology2025
CT-based nomogram for predicting EGFR mutation status in ground-glass nodules of lung adenocarcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correlation analysis between growth heterogeneity and genetic mutations in resected subsolid lung adenocarcinoma based on long-term computed tomography (CT) follow-up.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to establish a nomogram based on computed tomography (CT) imaging characteristics to predict epidermal growth factor receptor (EGFR) mutation status in patients with ground-glass nodules (GGNs), thereby aiding medication decision-making. Materials and methods: In total, 935 patients diagnosed with GGNs were enrolled. Patients undergoing surgery from August 2019 to December 2023 (n=709) comprised the training cohort, whereas those treated between January 2024 and March 2025 (n=226) constituted the validation cohort. Clinical parameters and radiological features were recorded for all participants. The training group underwent univariate and multivariate logistic regression analyses to identify significant predictive variables, subsequently facilitating the construction of a nomogram prediction model. The model's discrimination, calibration, and clinical applicability were validated in both patient cohorts. Results: Multivariate logistic regression analysis revealed maximum nodule diameter, consolidation-to-tumor ratio (CTR), mean CT values, presence of air bronchogram signs, and vascular convergence signs as independent predictors of EGFR mutations. The resulting nomogram demonstrated robust predictive capability, achieving an area under the curve (AUC) of 0.87 (95% CI: 0.85-0.90) in the training group and 0.87 (95% CI: 0.82-0.92) in the validation group. Bootstrap internal validation yielded an AUC of 0.89, confirming strong model discrimination. Calibration plots and decision curve analysis further supported the model had a good calibration degree and clinical practicability across both groups. Conclusion: The nomogram integrating maximum diameter, CTR, mean CT value, air bronchogram signs, and vascular convergence signs effectively predicts EGFR mutation status in GGNs, offering a valuable tool for clinical guidance and patient management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.